Press Releases

Press Releases

Date News
Nov. 24, 2020 SUNSHINE BIOPHARMA BELIEVES THAT AN EFFECTIVE CORONAVIRUS TREATMENT CONTINUES TO BE NECESSARY
Nov. 19, 2020 Sunshine Biopharma Signs An Agreement With A Montreal-Based Company To Advance The Development Of Adva-27a Anticancer Compound
Nov. 10, 2020 Sunshine Biopharma Signs an Agreement for Distribution of Essential-9TM in Asia and the Far East
Oct. 26, 2020 SUNSHINE BIOPHARMA RECEIVES SECOND TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT
Oct. 19, 2020 SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP TO DEVELOP A NEW ANTI-CORONAVIRUS DRUG
Oct. 7, 2020 SUNSHINE BIOPHARMA IDENTIFIES A LEAD ANTI-CORONAVIRUS COMPOUND
Sep. 15, 2020 SUNSHINE BIOPHARMA SECURES $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT
Aug. 25, 2020 SUNSHINE BIOPHARMA COMPLETES THE SYNTHESIS OF FOUR POTENTIAL INHIBITORS OF CORONAVIRUS PROTEASE
Jun. 3, 2020 SUNSHINE BIOPHARMA FILES A PATENT APPLICATION FOR A NEW CORONAVIRUS COVID-19 TREATMENT
Nov. 6, 2019 SUNSHINE BIOPHARMA RECEIVES HEALTH CANADA APPROVAL FOR ESSENTIAL CALCIUM-VITAMIN DTM SUPPLEMENT
Oct. 17, 2019 SUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER
Sep. 3, 2019 Sunshine Biopharma Receives Vegan Certification for Essential 9™ Amino Acids Supplement
May 28, 2019 In Addition to Essential 9™, Sunshine Biopharma Launches 7 New Dietary Supplements Now Available on Amazon.ca
May 16, 2019 Sunshine Biopharma Announces that Essential 9™ is Now Available in the United States on Amazon.com
Mar. 12, 2019 SUNSHINE BIOPHARMA ANNOUNCES THAT ESSENTIAL 9™ IS NOW AVAILABLE ON AMAZON.CA
Feb. 4, 2019 Sunshine Biopharma Receives Notice Of Allowance For A New Patent Application Extending Protection Of Adva-27a Anticancer Drug Until 2033
Dec. 17, 2018 Sunshine Biopharma Receives Health Canada Approval for Essential 9™, The Company’s First Over The Counter Essential Micronutrient
Dec. 12, 2018 Sunshine Biopharma Signs an Agreement With Crocus Laboratories for Manufacturing of Adva-27a Anticancer Drug
Sep. 14, 2018 Sunshine Biopharma Announces $10 Million Equity Financing
Aug. 16, 2018 Sunshine Biopharma Signs A Service Agreement With Utah Based Quintessential Biosciences Inc.
Jun. 18, 2018 Sunshine Biopharma Launches Microbiology Testing Service
May 10, 2018 Sunshine Biopharma Annouces Extension Of The Term Of Its Brokered Up To $10 Million Private Placement Financing
Jan. 4, 2018 Sunshine Biopharma Completes the Acquisition of Atlas Pharma
Sep. 5, 2017 Sunshine Biopharma Enters Into An Investment Banking Agreement With Jitney Trade To Raise Up To $10 Million For Clinical Trials Of Adva-27a Anticancer Drug
Jun. 26, 2017 Sunshine Biopharma Releases Results of Independent Valuation
Jun. 19, 2017 Sunshine Biopharma Files An Application With Health Canada For A Drug Establishment License
Jan. 11, 2017 Sunshine Biopharma Currently Reviewing Twenty Three Additional Generic Products For In-licensing
Dec. 9, 2016 Sunshine Biopharma Signs Strategic Alliance Agreement With Atlas Pharma
Jun. 30, 2016 Sunshine Biopharma Signs Licensing Agreement For Three Additional Generic Products For Treatment Of Cancer And BPH
May 11, 2016 Sunshine Biopharma Signs Licensing Agreement For Anastrozole, The Company’s First Generic Drug For Treatment Of Breast Cancer
Mar. 15, 2016 Sunshine Biopharma Eliminates The Debt Obligations Associated With The Recently Acquired Patents For It’s Adva-27a Anticancer Compound
Jan. 20, 2016 Sunshine Biopharma Is Moving Forward With Its Development Plans For Adva-27a Anticancer Compound
Dec. 28, 2015 Sunshine Biopharma Acquires All Remaining Worldwide Patents For Its Adva-27a Anticancer Compound
Oct. 9, 2015 Sunshine Biopharma Acquires The US Patent For Its Anticancer Compound, Adva-27a
Aug. 4, 2015 Sunshine Biopharma Announces That The Initial Manufacturing Sample Of Its Anticancer Compound Adva-27a Meets Biological Specifications Paving The Way For Clinical Trials
May 26, 2015 Sunshine Biopharma To Receive This Week A Sample From The Adva-27a Manufacturing Currently Underway At Lonza In Switzerland
Mar. 24, 2015 Sunshine Biopharma Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In India
Feb. 25, 2015 Sunshine Biopharma Announces Change To Its Board Of Directors And Officers
Nov. 19, 2014 Sunshine Biopharma Signs Agreement With Lonza To Manufacture Its Lead Anticancer Compound, Adva-27a
Nov. 3, 2014 Ebola Virus Infections Could Potentially Be Treated With Sunshine Biopharma’s Lead Anticancer Compound, Adva-27a
Oct. 14, 2014 Sunshine Biopharma Retains Renmark Financial Communications To Provide Investor Relations
Oct. 1, 2014 Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Completes The Sop’s Required By Health Canada To Secure Drug Establishment License
Sep. 3, 2014 Sunshine Biopharma Negotiating With Cro’s To Initiate Master Drug File For Adva-27a Anticancer Compound
Aug. 21, 2014 Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Engages Health Canada Specialized Consultants To Secures Pharmaceutical Establishment License
Aug. 11, 2014 Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Secures Dedicated Space To Commence Global Generic Pharmaceutical Operations
Jun. 9, 2014 Sunshine Biopharma’s Adva-27a Featured In 2014 Worldwide Uterine Cancer Report For Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells
May 12, 2014 Sunshine Biopharma Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In Canada
Apr. 29, 2014 Sunshine Biopharma Secures Funding For Its Adva-27a Anticancer Compound From Dutchess Opportunity Fund II
Apr. 7, 2014 Sunshine Biopharma Increases The Effectiveness Of Adva-27a Lead Compound 9.5-fold Against Breast And Pancreatic Cancer In Vitro
Mar. 31, 2014 Management Of Sunshine Biopharma Alarmed By The Recent World Health Organization Report That Cancer Is On The Rise
Feb. 14, 2014 Sunshine Biopharma Begins Construction Of Mouse Xenograft Models For Pancreatic Cancer To Advance Adva-27a As A Treatment For This Deadly Form Of Cancer
Jun. 19, 2013 Sunshine Biopharma’s Anticancer Drug Candidate, Adva-27a, Is Unaffected By The Recent Supreme Court Ruling
Jun. 4, 2013 Sunshine Biopharma Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer Cells
May 1, 2013 Sunshine Biopharma Narrows Kilogram Manufacturing Options For Adva-27a Breast Cancer Drug Candidate to Three Suppliers
Apr. 9, 2013 Sunshine Biopharma HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic at High Concentrations
Mar. 14, 2013 Sunshine Biopharma Commences Negotiations with Contract Manufacturing Organizations for Production of its Multidrug-Resistant Breast Cancer Drug, Adva-27a
Feb. 26, 2013 Sunshine Biopharma Reports on IND Research for its Novel Breast Cancer Drug Candidate, Adva-27a
Jan. 15, 2013 Advanomics Corporation, The Parent Company of Sunshine Biopharma, Files A New Patent Application For Its Multidrug Resistance Adva-27a Anticancer Compound
Dec. 10, 2012 Sunshine Biopharma Completes Another IND-Enabling Study: Adva-27a Is Found To Be Effective Against Multidrug Resistant Uterine Cancer Cells
Dec. 4, 2012 Sunshine Biopharma Completes Six IND-Enabling Studies for its Anticancer Compound, Adva-27a
Nov. 27, 2012 Advanomics Corporation, The Parent Company of Sunshine Biopharma, Completes Acquisition of Adva-27a Patents
Nov. 13, 2012 Sunshine Biopharma Initiates IND-Enabling Studies For Its Anticancer Compound, Adva-27a
Oct. 9, 2012 Sunshine Biopharma Receives Scale-Up Manufacturing Protocol For Its Lead Anti-Cancer Compound, Adva-27a
Sep. 25, 2012 Sunshine Biopharma’s Adva-27a Preclinical Research Results to be Published in Oct. Issue of ANTICANCER RESEARCH
Sep. 20, 2012 Breast Cancer News: Geron Drug Fails, Herceptin® May Increase Heart Problems, Sunshine Biopharma Heading for Clinical Trials
Sep. 13, 2012 Sunshine Biopharma Advances to Next Phase of Drug Development with Lead Anti-Cancer Compound, ADva-27a
Sep. 4, 2012 Sunshine Biopharma Takes Delivery of Newly Manufactured Batch of Adva-27a and Proceeds to Conducting Biological Verification of the Compound’s Anti-Cancer Activity
Aug. 15, 2012 Sunshine Biopharama Announces Submission of an Adva-27a Manuscript for Publication in a Peer-Reviewed Scientific Journal
Aug. 3, 2012 BUYINS.NET Issues Sunshine Biopharma Squeeze Trigger Report
Jul. 30, 3012 Sunshine Biopharma, Inc. (OTCBB: SBFM) – Targeting the Challenge of Multidrug Resistance in Breast and Lung Cancer by Developing Adva-27a
Jul. 24, 2012 Biotech Investor Alert: CFO of Sunshine Biopharma (OTCBB: SBFM) Expands on Significance of Recent Manufacturing News of Lead Anti-Cancer Compound Adva-27a
Jul. 11, 2012 Sunshine Biopharma Engages Beta Pharma Canada For Manufacturing of an Initial Batch of Adva-27a
Jul. 9, 2012 Targeting Aggressive Forms of Cancer: Sunshine Biopharma (OTCBB:SBFM) and Roche (SIX: RO, ROG; OTCQX: RHHBY)
Jul. 2, 2012 Biotech Investor Q&A with CFO of Sunshine Biopharma (OTCBB:SBFM) Discussing its Lead Compound – Adva-27a for Aggressive Forms of Cancer
Jun. 26, 2012 Sunshine Biopharma’s Adva-27a Found to be Effective at Killing Multidrug Resistant Lung Cancer Cells
May 22, 2012 Pharmacokinetics Parameters of Sunshine Biopharma’s Lead Anti-Cancer Compound Exceed Expectations>
Apr. 9, 2012 Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering its Adva-27a Anti-Cancer Compound
Mar. 26, 2012 Sunshine Biopharma and Binghamton University to Present New Data at the Upcoming American Association for Cancer Research Meeting in Chicago
Nov. 28, 2011 Avastin Ousted by FDA for Breast Cancer, Sunshine Biopharma Gears-Up for Clinicals
Nov. 15, 2011 Sunshine Biopharma’s Announces Successful Completion of Preclinical Studies for Adva-27a, The Company’s Lead Anti-Cancer Compound
Oct. 5, 2011 Sunshine Biopharma’s Anti-Cancer Compound, Adva-27a, found to be a Topoisomerase II Inhibitor
Aug. 30, 2011 Clearance of Sunshine Biopharma’s Anti-Cancer Compound, Adva-27a, Does Not Involve a Toxic Intermediate
Jul. 27, 2011 Sunshine Biopharma Looking to Mimic Roche’s Billion Dollar Cancer Drug Success
Jul. 25, 2011 Sunshine Biopharma’s Lead Anti-tumor Compound, Adva-27a, is cleared via a cytochrome P450-Independent Mechanism
Jul. 11, 2011 Sunshine Biopharma’s Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells
Jun. 27, 2011 Sunshine Biopharma’s Lead Anti-Cancer Compound, Adva-27a, performs exceptionally well in human microsome stability assays
Jun. 17, 2011 Sunshine Biopharma enters into clinical trials agreement with the Jewish General Hospital in Montreal, Canada
Apr. 1, 2011 Sunshine Biopharma’s CEO Does Live Interview on ChartPoppers.com
Mar. 4, 2011 CEO CFO Interviews Dr. Steve N. Slilaty
Feb. 25, 2011 Interview with Central NY Business Journal
Jan. 26, 2011 FOX 40 WICZ.COM Interview of Binghamton University on Sunshine BioPharma Part 1
Jan. 21, 2011 Sunshine Biopharma And Binghamton University (State University Of New York) Enter Into Research Agreement
Oct. 26, 2010 CEOCAST Interview with Dr. Steve Slilaty of Sunshine BioPharma Inc.
Oct. 13, 2010 Sunshine Biopharma, Inc. Begins Drug Development Activities
Oct. 20, 2009 Mountain West Business Solutions Acquires Sunshine Biopharma